DK187889D0 - Dna-forbindelser og klonende vektorer, der koder for det monoklonale antistof ks1/4, samt chimere antistoffer afledt af ks1/4 og rettet mod et humant adenocarcinoma-antigen - Google Patents

Dna-forbindelser og klonende vektorer, der koder for det monoklonale antistof ks1/4, samt chimere antistoffer afledt af ks1/4 og rettet mod et humant adenocarcinoma-antigen

Info

Publication number
DK187889D0
DK187889D0 DK187889A DK187889A DK187889D0 DK 187889 D0 DK187889 D0 DK 187889D0 DK 187889 A DK187889 A DK 187889A DK 187889 A DK187889 A DK 187889A DK 187889 D0 DK187889 D0 DK 187889D0
Authority
DK
Denmark
Prior art keywords
chimerary
directed
monoclonal antibody
cloning vectors
antibodies derived
Prior art date
Application number
DK187889A
Other languages
English (en)
Other versions
DK187889A (da
Inventor
Lisa Selsam Beavers
Thomas Frank Bumol
Robert Alan Gadski
Barbara Jean Weigel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DK187889D0 publication Critical patent/DK187889D0/da
Publication of DK187889A publication Critical patent/DK187889A/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK187889A 1988-04-21 1989-04-19 Dna-forbindelser og klonende vektorer, der koder for det monoklonale antistof ks1/4, samt chimere antistoffer afledt af ks1/4 og rettet mod et humant adenocarcinoma-antigen DK187889A (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/184,522 US4975369A (en) 1988-04-21 1988-04-21 Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen

Publications (2)

Publication Number Publication Date
DK187889D0 true DK187889D0 (da) 1989-04-19
DK187889A DK187889A (da) 1989-10-23

Family

ID=22677247

Family Applications (1)

Application Number Title Priority Date Filing Date
DK187889A DK187889A (da) 1988-04-21 1989-04-19 Dna-forbindelser og klonende vektorer, der koder for det monoklonale antistof ks1/4, samt chimere antistoffer afledt af ks1/4 og rettet mod et humant adenocarcinoma-antigen

Country Status (14)

Country Link
US (1) US4975369A (da)
EP (1) EP0338767A3 (da)
JP (1) JPH02211877A (da)
KR (1) KR900016459A (da)
CN (1) CN1037174A (da)
AU (1) AU621600B2 (da)
DK (1) DK187889A (da)
HU (1) HUT50870A (da)
IL (1) IL90016A0 (da)
NZ (1) NZ228801A (da)
PH (1) PH26945A (da)
PT (1) PT90312A (da)
RU (1) RU1780541C (da)
ZA (1) ZA892840B (da)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0364096B1 (en) 1988-09-06 2000-03-08 Xoma Corporation Gene expression elements and the production of chimeric mouse-human antibodies
IL89490A0 (en) * 1988-11-17 1989-09-10 Hybritech Inc Chimeric antibodies directed against metal chelates
WO1991006649A1 (fr) * 1989-11-07 1991-05-16 The Green Cross Corporation Fragment de gene de la region v d'un anticorps de souris et preparation d'anticorps chimeriques par l'utilisation dudit fragment de gene
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
AU1337092A (en) * 1991-01-29 1992-08-27 Brigham And Women's Hospital A cdna encoding the type i iodothyronine 5' deiodinase
US5272078A (en) * 1991-01-29 1993-12-21 Brigham And Women's Hospital CDNA encoding the type I iodothyronine 5'deiodinase
US20050196400A1 (en) * 1991-05-06 2005-09-08 Xoma Technology Ltd. Production of chimeric mouse-human antibodies with specificity to human tumor antigens
US5756096A (en) * 1991-07-25 1998-05-26 Idec Pharmaceuticals Corporation Recombinant antibodies for human therapy
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
MX9204374A (es) * 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US6004555A (en) * 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US6036955A (en) * 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
US6749853B1 (en) * 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US6093399A (en) * 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
FR2724320B1 (fr) * 1994-09-13 1996-12-20 Transgene Sa Nouvel implant pour le traitement des maladies acquises
US6440418B1 (en) * 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
CA2257357C (en) 1996-06-07 2010-04-13 Neorx Corporation Humanized antibodies with modified glycosylation
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6420140B1 (en) * 1996-10-11 2002-07-16 Abgenix, Inc. Production of multimeric protein by cell fusion method
US6348581B1 (en) 1996-10-31 2002-02-19 The Dow Chemical Company High affinity humanized anti-TAG-72 monoclonalantibodies
DK0966533T3 (da) 1997-02-07 2010-01-04 Us Gov Health & Human Serv Aktivitetsafhængig neurotrof faktor III (ADNF III).
US6893636B2 (en) * 1997-02-20 2005-05-17 Biogen Idec Ma Inc. Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US7033589B1 (en) 1997-02-20 2006-04-25 Biogen Idec Ma Inc. γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US7147854B2 (en) * 1997-06-23 2006-12-12 Yes Biotech Laboratories Ltd. Topical treatment of psoriasis using neutralizing antibodies to interleukin-8
AU763719B2 (en) * 1997-12-08 2003-07-31 Merck Patent Gmbh Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
WO1999059578A1 (en) 1998-05-19 1999-11-25 Research Development Foundation Triterpene compositions and methods for use thereof
US6350452B1 (en) 1998-09-24 2002-02-26 Promega Corporation Apoptosis marker antibodies and methods of use
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
US20030143233A1 (en) * 1999-06-07 2003-07-31 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
US20030103948A1 (en) * 1999-06-07 2003-06-05 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
US7144991B2 (en) 1999-06-07 2006-12-05 Aletheon Pharmaceuticals, Inc. Streptavidin expressed gene fusions and methods of use thereof
EP1731531B1 (en) 1999-08-09 2012-05-30 Merck Patent GmbH Multiple cytokine-antibody complexes
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
CA2399832C (en) 2000-02-11 2011-09-20 Stephen D. Gillies Enhancing the circulating half-life of antibody-based fusion proteins
CA2410188A1 (en) * 2000-06-06 2001-12-13 Idec Pharmaceutical Corporation Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof
AU2001271729B2 (en) 2000-06-29 2007-01-04 Merck Patent Gmbh Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
US20060148732A1 (en) * 2000-11-17 2006-07-06 Gutterman Jordan U Inhibition of NF-kappaB by triterpene compositions
KR20090010127A (ko) 2001-03-07 2009-01-28 메르크 파텐트 게엠베하 하이브리드 이소타입 항체 부분구조를 포함하는 단백질을 위한 발현 기술
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
DE60239454D1 (de) * 2001-05-03 2011-04-28 Merck Patent Gmbh Rekombinanter, tumorspezifischer antikörper und dessen verwendung
DE60238435D1 (de) * 2001-10-26 2011-01-05 Scripps Research Inst Gezielte thrombose durch gewebefaktor polypeptiden
PT1454138E (pt) 2001-12-04 2012-03-28 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
CN104225610B (zh) 2002-07-15 2017-03-01 得克萨斯大学体系董事会 与阴离子磷脂和氨基磷脂结合的选定抗体及其治疗用途
WO2005016232A2 (en) 2002-08-01 2005-02-24 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US20040053363A1 (en) * 2002-09-18 2004-03-18 Thomas Ryll Method for production of a multimeric protein by cell fusion
US20040053359A1 (en) * 2002-09-18 2004-03-18 Thomas Ryll Method for production of a multimeric protein by cell fusion
JP4033390B2 (ja) * 2002-10-30 2008-01-16 独立行政法人科学技術振興機構 不死化ナチュラルキラー細胞株
RU2366664C2 (ru) 2002-12-17 2009-09-10 Мерк Патент Гмбх Гуманизированное антитело (н14.18) на основании антитела 14.18 мыши, связывающееся с gd2, и его слияние с il-2
EP2397189B1 (en) 2003-11-14 2015-03-18 Brigham and Women's Hospital, Inc. Methods of modulating immunity
BRPI0417916A (pt) 2003-12-31 2007-04-10 Merck Patent Gmbh proteìna de fusão de fc-eritropoietina com farmacocinética melhorada
AU2005206277B2 (en) 2004-01-22 2011-06-23 Merck Patent Gmbh Anti-cancer antibodies with reduced complement fixation
WO2007094754A2 (en) 2005-01-27 2007-08-23 The Regents Of The University Of Califordnia Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
RU2432962C2 (ru) 2005-01-27 2011-11-10 Чилдрен'З Хоспитал Энд Рисерч Сентер Эт Окленд Вакцины с использованием везикул на основе gna 1870 широкого спектра действия для профилактики заболеваний, вызываемых neisseria meningitidis
PT1966245E (pt) 2005-12-30 2011-08-31 Merck Patent Gmbh Anticorpos anti-cd19 com imunogenicidade reduzida
CA2699394C (en) 2007-09-17 2020-03-24 The Regents Of The University Of California Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
MX2010005104A (es) 2007-11-09 2010-08-04 Peregrine Pharmaceuticals Inc Composiciones de anticuerpo anti-factor de crecimiento endotelial vascular y metodos.
EP3029061B1 (en) 2008-06-18 2017-09-13 The Texas A&M University System Mesenchymal stem cells, compositions, and methods for treatment of cardiac tissue damage
US20110177614A1 (en) 2010-01-15 2011-07-21 The Regents Of The University Of California Compositions and methods for detecting cancer
CA2787755A1 (en) 2010-01-20 2011-07-28 Tolerx, Inc. Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
EP2525813B1 (en) 2010-01-20 2017-01-04 Merck Sharp & Dohme Corp. Anti-ilt5 antibodies and ilt5-binding antibody fragments
AU2011230590C1 (en) 2010-03-26 2016-09-15 Memorial Sloan-Kettering Cancer Center Antibodies to MUC16 and methods of use thereof
EP3848394A1 (en) 2010-04-09 2021-07-14 Critical Care Diagnostics, Inc. Soluble human st-2 antibodies and assays
JP2013525420A (ja) 2010-04-29 2013-06-20 ナスバックス リミテッド 抗ｃｄ３免疫分子療法により肝炎を治療する方法および組成物
CA2809363A1 (en) 2010-08-24 2012-03-01 Abbott Laboratories Hiv core protein specific antibodies and uses thereof
US20120148559A1 (en) 2010-12-01 2012-06-14 Board Of Regents The University Of Texas System Compositions and method for deimmunization of proteins
WO2013151649A1 (en) 2012-04-04 2013-10-10 Sialix Inc Glycan-interacting compounds
EP2836514A4 (en) 2012-04-13 2015-12-30 Childrens Medical Center TIKI INHIBITORS
WO2014093417A1 (en) 2012-12-12 2014-06-19 University Of Virginia Patent Foundation Compositions and methods for regulating erythropoiesis
US10081673B2 (en) 2013-03-14 2018-09-25 Ffe Therapeutics Llc Compositions and methods for treating angiogenesis-related disorders
MX2017006167A (es) 2014-11-12 2018-03-23 Siamab Therapeutics Inc Compuestos que interactúan con glicanos y métodos de uso.
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
RU2758113C2 (ru) 2015-03-17 2021-10-26 Мемориал Слоан-Кеттеринг Кэнсер Сентер Антитела к muc16 и их применение
CN108139375A (zh) 2015-06-26 2018-06-08 贝斯以色列女执事医疗中心股份有限公司 靶向髓样衍生的抑制细胞中的四跨膜蛋白33(tspan33)的癌症疗法
MX2018005061A (es) 2015-11-12 2019-02-28 Siamab Therapeutics Inc Compuestos de interacción con glicanos y métodos de uso.
PT3383920T (pt) 2015-11-30 2024-04-15 Univ California Entrega de carga útil específica para tumores e ativação imune utilizando um anticorpo humano que tem como alvo um antigénio altamente específico da superfície das células tumorais
EP3541847A4 (en) 2016-11-17 2020-07-08 Seattle Genetics, Inc. COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
MX2019010202A (es) 2017-03-03 2019-10-02 Seattle Genetics Inc Compuestos que interactuan con glicano y metodos de uso.
CN108727494A (zh) * 2017-04-25 2018-11-02 成都贝爱特生物科技有限公司 一种靶向筛选外源基因双整合位点提高人c5单抗表达产量的方法
WO2019018744A1 (en) 2017-07-21 2019-01-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services IMMUNOGENIC COMPOSITIONS OF NEISSERIA MENINGITIDIS
US20200283537A1 (en) 2017-11-14 2020-09-10 University Of Virginia Patent Foundation Compositions and methods for making and using bispecific antibodies
TW202015726A (zh) 2018-05-30 2020-05-01 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
CU20200089A7 (es) 2018-06-01 2021-07-02 Novartis Ag Moléculas de unión contra bcma
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
EP3972993A1 (en) 2019-05-21 2022-03-30 Novartis AG Variant cd58 domains and uses thereof
JOP20210309A1 (ar) 2019-05-21 2023-01-30 Novartis Ag جزيئات ربط بـ cd19 واستخدامتها
US20230340086A1 (en) 2019-06-19 2023-10-26 Christopher Roland Oelkrug Antibody-mediated neutralization of beta-lactamases
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
EP4058481A1 (en) 2019-11-15 2022-09-21 Pliant Therapeutics, Inc. Compositions and methods for activation of integrins
US20210284743A1 (en) 2020-03-10 2021-09-16 Tiziana Life Sciences Plc Compositions of il-6/il-6r antibodies and methods of use thereof
WO2021255189A1 (en) 2020-06-17 2021-12-23 Tiziana Life Sciences, Plc Compositions and methods for augmenting chimeric antigen receptor (car) t cell therapies
CN116406274A (zh) 2020-07-30 2023-07-07 迪赞纳生命科学公开有限公司 用于治疗冠状病毒的cd3抗体
CN116419747A (zh) 2020-08-07 2023-07-11 福蒂斯治疗公司 靶向cd46的免疫偶联物及其使用方法
CA3199839A1 (en) 2020-11-06 2022-05-12 Novartis Ag Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
IL302569A (en) 2020-11-06 2023-07-01 Novartis Ag CD19 binding molecules and their uses
WO2022162569A1 (en) 2021-01-29 2022-08-04 Novartis Ag Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
PE20240086A1 (es) 2021-04-14 2024-01-16 Villaris Therapeutics Inc Anticuerpos anti-cd122 y usos de estos
US20220332822A1 (en) 2021-04-16 2022-10-20 Tiziana Life Sciences Plc Subcutaneous administration of antibodies for the treatment of disease
WO2023064942A1 (en) 2021-10-14 2023-04-20 Tiziana Life Sciences Plc Methods of suppressing microglial activation
IL312584A (en) 2021-11-09 2024-07-01 Sensei Biotherapeutics Inc ANTI-VISTA antibodies and their uses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0173494A3 (en) * 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) * 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
EP0245949B1 (en) * 1986-04-09 1997-10-29 Eli Lilly And Company A method of using eukaryotic expression vectors comprising the bk virus enhancer
DE3751908T2 (de) * 1986-07-07 1997-02-06 Centocor Inc Chimärisches Murine-Mensch-Immunoglobulin, spezifisch für tumorassoziertes 17-1A Antigen

Also Published As

Publication number Publication date
EP0338767A3 (en) 1991-07-17
PH26945A (en) 1992-12-03
US4975369A (en) 1990-12-04
IL90016A0 (en) 1989-12-15
AU621600B2 (en) 1992-03-19
DK187889A (da) 1989-10-23
ZA892840B (en) 1990-12-28
PT90312A (pt) 1989-11-10
JPH02211877A (ja) 1990-08-23
NZ228801A (en) 1991-05-28
EP0338767A2 (en) 1989-10-25
HUT50870A (en) 1990-03-28
KR900016459A (ko) 1990-11-13
RU1780541C (ru) 1992-12-07
CN1037174A (zh) 1989-11-15
AU3318989A (en) 1989-10-26

Similar Documents

Publication Publication Date Title
DK187889A (da) Dna-forbindelser og klonende vektorer, der koder for det monoklonale antistof ks1/4, samt chimere antistoffer afledt af ks1/4 og rettet mod et humant adenocarcinoma-antigen
DK666389A (da) Monoklonalt antistof
DE68914244D1 (de) Monoklonaler Antikörper.
FI914908A0 (fi) Ny monoklonal antikropp med ny antigen relaterad till humana tumoerer.
DK108589A (da) Chimere antistoffer rettet mod humant carcinoembryonalt antigen samt dna-sekvenser, der koder for saadanne antistoffer
DE3854502D1 (de) Gegen hiv-antigene spezifischer monoklonaler antikörper.
DK108189D0 (da) Chimere antistoffer rettet mod humant carcinoembryonalt antigen og metal-chelater samt dna-sekvenser, der koder for saadanne antistoffer
DK397184A (da) Antigener og monoklone antistoffer, der er reaktive mod eimeriaarters sporozoitter
DE3885355D1 (de) Monoklonale Antikörper.
DK162170C (da) Monoklonale antistoffer, der er reaktive mod eimeriaarters merozoitter
DK63187D0 (da) Krydsbeskyttende monoklonale antistofpraeparater
DE3177276D1 (de) Monoklonale antikoerper.
DK191989D0 (da) Tumor-associeret glycoproteinantigen, antistoffer mod antigenet samt hybridoma-cellelinie, der producerer antistofferne
DK188185D0 (da) Monoklonalt antistof
NO894444L (no) Anti-fucosylceramid monoklonalt antistoff.
DK717888A (da) Monoklonale antistoffer
DE3586808D1 (de) L-thyroxin erkennende monoklonale antikoerper.
DK144485D0 (da) Monoklonale antistoffer
DK37785A (da) Monoclonalt antistof
DK49291A (da) Gramnegativ-bakterieendotoxinblokerende, monoklonale antistoffer
DE3785795D1 (de) Monoklonale anti-menschliche magenkrebs-antikoerper.
DK474189A (da) Monoklonalt antistof
NO873488D0 (no) Monoklonale antistoffer.
NO890116D0 (no) Monoklonale antistoffer.
DK288788D0 (da) Immunodiagnoseanalyser under anvendelse af kimaere antigener

Legal Events

Date Code Title Description
ATS Application withdrawn